168 related articles for article (PubMed ID: 30542835)
1. Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells.
Curless BP; Uko NE; Matesic DF
Invest New Drugs; 2019 Oct; 37(5):902-911. PubMed ID: 30542835
[TBL] [Abstract][Full Text] [Related]
2. Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells.
Ali A; Sidorova TS; Matesic DF
Invest New Drugs; 2013 Jun; 31(3):525-34. PubMed ID: 23054210
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt promotes feedforward mTORC2 activation through IKKα.
Dan HC; Antonia RJ; Baldwin AS
Oncotarget; 2016 Apr; 7(16):21064-75. PubMed ID: 27027448
[TBL] [Abstract][Full Text] [Related]
4. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
Razmara M; Monazzam A; Skogseid B
Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
7. mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells.
Moschella PC; McKillop J; Pleasant DL; Harston RK; Balasubramanian S; Kuppuswamy D
Cell Signal; 2013 Sep; 25(9):1904-12. PubMed ID: 23673367
[TBL] [Abstract][Full Text] [Related]
8. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
9. A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation.
Yang G; Murashige DS; Humphrey SJ; James DE
Cell Rep; 2015 Aug; 12(6):937-43. PubMed ID: 26235620
[TBL] [Abstract][Full Text] [Related]
10. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
11. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells.
Matesic DF; Villio KN; Folse SL; Garcia EL; Cutler SJ; Cutler HG
Cancer Chemother Pharmacol; 2006 Jun; 57(6):741-54. PubMed ID: 16254733
[TBL] [Abstract][Full Text] [Related]
14. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of mTORC2 by integrin αIIbβ3 is required for PI3Kβ-dependent activation of Akt but is dispensable for platelet spreading on fibrinogen.
Torti M; Manganaro D; Visconte C; Zarà M; Canino J; Vismara M; Canobbio I; Guidetti GF
Platelets; 2020 May; 31(4):521-529. PubMed ID: 31509054
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide-dependent kinase 1 and mTORC2 synergistically maintain postnatal heart growth and heart function in mice.
Zhao X; Lu S; Nie J; Hu X; Luo W; Wu X; Liu H; Feng Q; Chang Z; Liu Y; Cao Y; Sun H; Li X; Hu Y; Yang Z
Mol Cell Biol; 2014 Jun; 34(11):1966-75. PubMed ID: 24662050
[TBL] [Abstract][Full Text] [Related]
18. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma.
Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M
Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696
[TBL] [Abstract][Full Text] [Related]
19. Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival.
He J; Zhao J; Quan Y; Hou X; Yang M; Dong Z
Front Immunol; 2020; 11():617404. PubMed ID: 33633735
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
